{"seq": 1, "ts": "2026-02-20T10:25:09.284407+00:00", "agent": "agent2", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nCommands:\n  init        Initialize audit trail and cache (.pm/)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  quick       One-command search pipeline (outputs JSONL)\n\nExamples:\n  pm search \"CRISPR cancer\" | pm fetch | pm parse > results.jsonl\n  pm quick \"covid vaccine\" --max 50\n  pm filter --year 2024 --has-abstract < articles.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": ""}
{"seq": 2, "ts": "2026-02-20T10:25:16.848191+00:00", "agent": "agent2", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nExamples:\n  pm search \"CRISPR cancer therapy\"\n  pm search --max 100 \"machine learning\"\n  pm search \"covid vaccine 2024\" | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": ""}
{"seq": 3, "ts": "2026-02-20T10:25:23.775468+00:00", "agent": "agent2", "cmd": "pm fetch --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm fetch - Fetch PubMed XML from E-utilities API\n\nUsage: echo \"12345\" | pm fetch > articles.xml\n       cat pmids.txt | pm fetch > articles.xml\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nInput:\n  PMIDs from stdin, one per line\n\nOutput:\n  PubMed XML to stdout\n\nFeatures:\n  - Batches requests (200 PMIDs per API call)\n  - Rate limits to ~3 requests/second\n  - Exits with error on network failure\n\nExamples:\n  echo \"12345\" | pm fetch > article.xml\n  cat pmids.txt | pm fetch > articles.xml\n  pm search \"CRISPR\" | pm fetch | pm parse > results.jsonl\n", "stderr": ""}
{"seq": 4, "ts": "2026-02-20T10:25:30.308426+00:00", "agent": "agent2", "cmd": "pm parse --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm parse - Parse PubMed XML to JSONL\n\nUsage: cat articles.xml | pm parse [OPTIONS] > articles.jsonl\n       zcat articles.xml.gz | pm parse [OPTIONS] > articles.jsonl\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nOutput:\n  One JSON object per line (JSONL format) with fields:\n    pmid, title, authors, journal, year, date, doi, pmcid, abstract\n\nExamples:\n  cat pubmed.xml | pm parse > articles.jsonl\n  zcat pubmed25n0001.xml.gz | pm parse > articles.jsonl\n  cat pubmed.xml | pm parse --verbose > articles.jsonl 2>progress.log\n", "stderr": ""}
{"seq": 5, "ts": "2026-02-20T10:25:37.992355+00:00", "agent": "agent2", "cmd": "pm search PSMA PET metabolic tumor volume prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 6, "ts": "2026-02-20T10:25:46.874465+00:00", "agent": "agent2", "cmd": "pm search PSMA PET metabolic tumor volume prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 8, "ts": "2026-02-20T10:25:46.888825+00:00", "agent": "agent2", "cmd": "pm fetch --verbose", "exit_code": 0, "stdin_lines": 100, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\"><PMID Version=\"1\">41703276</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2730-664X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2026</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Communications medicine</Title><ISOAbbreviation>Commun Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Distinct prognostic value of [<sup>18</sup>F]FDG PET and [<sup>68</sup>Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s43856-026-01444-6</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">This study aimed to eva\n... [2144965 chars total, truncated] ...\nnd imaging derived parameters before and after two cycles of therapy. Nuklearmedizin. 2019;58:443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31724145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmuck S, von Klot CA, Henkenberens C. et al. Initial Experience with Volumetric 68Ga-PSMA I&amp;T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017;58:1962&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28522740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidkonz C, Cordes M, Schmidt D. et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29725716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>", "stderr": "Fetching batch 1 (100 PMIDs)...\n"}
{"seq": 7, "ts": "2026-02-20T10:25:46.884361+00:00", "agent": "agent2", "cmd": "pm parse", "exit_code": 0, "stdin_lines": 340, "stdout": "", "stderr": ""}
{"seq": 11, "ts": "2026-02-20T10:26:18.029221+00:00", "agent": "agent2", "cmd": "pm search PSMA PET metabolic tumor volume prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 9, "ts": "2026-02-20T10:26:18.019247+00:00", "agent": "agent2", "cmd": "pm fetch", "exit_code": 0, "stdin_lines": 100, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\"><PMID Version=\"1\">41703276</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2730-664X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2026</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Communications medicine</Title><ISOAbbreviation>Commun Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Distinct prognostic value of [<sup>18</sup>F]FDG PET and [<sup>68</sup>Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s43856-026-01444-6</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">This study aimed to eva\n... [2144965 chars total, truncated] ...\nnd imaging derived parameters before and after two cycles of therapy. Nuklearmedizin. 2019;58:443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31724145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmuck S, von Klot CA, Henkenberens C. et al. Initial Experience with Volumetric 68Ga-PSMA I&amp;T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017;58:1962&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28522740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidkonz C, Cordes M, Schmidt D. et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29725716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>", "stderr": ""}
{"seq": 10, "ts": "2026-02-20T10:26:18.028672+00:00", "agent": "agent2", "cmd": "pm parse --verbose", "exit_code": 0, "stdin_lines": 339, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were col\n... [412080 chars total, truncated] ...\nA. Patients with partial remission, independently assessed by each method, had better overall survival (OS) than patients with either stable or progressive disease. The difference in OS was statistically significant for the molecular imaging response assessment (median OS not reached vs. 8.3 m, p = 0.044), but not for the biochemical response assessment (median OS 18.1 m vs. 9.4 m, p = 0.468). Conclusion: Based on both assessment methods, [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy is an effective treatment for the highly challenging cohort of patients with mCRPC who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Molecular imaging response and biochemical PSA response were mostly concordant, though a considerable number of cases (29.4%) were discordant. Molecular imaging response reflecting the change in total viable tumour burden appears to be superior to PSA change in estimating survival outcome after tandem therapy.\", \"pmcid\": \"PMC7977444\", \"doi\": \"10.7150/thno.56211\"}\n", "stderr": "Parsed article 1: PMID 41703276\nParsed article 2: PMID 41635089\nParsed article 3: PMID 41519653\nParsed article 4: PMID 41490309\nParsed article 5: PMID 41486328\nParsed article 6: PMID 41454834\nParsed article 7: PMID 41421031\nParsed article 8: PMID 41363980\nParsed article 9: PMID 41344853\nParsed article 10: PMID 41287510\nParsed article 11: PMID 41281171\nParsed article 12: PMID 41266250\nParsed article 13: PMID 41167722\nParsed article 14: PMID 41067860\nParsed article 15: PMID 41021003\nParsed article 16: PMID 40967759\nParsed article 17: PMID 40851054\nParsed article 18: PMID 40788167\nParsed article 19: PMID 40696478\nParsed article 20: PMID 40665782\nParsed article 21: PMID 40665456\nParsed article 22: PMID 40647625\nParsed article 23: PMID 40605658\nParsed article 24: PMID 40551434\nParsed article 25: PMID 40550326\nParsed article 26: PMID 40517368\nParsed article 27: PMID 40397137\nParsed article 28: PMID 40278858\nParsed article 29: PMID 40259392\nParsed article 30: PMID 40247813\nParsed article 31: \n... [3258 chars total, truncated] ...\n 38285206\nParsed article 70: PMID 38199184\nParsed article 71: PMID 38117551\nParsed article 72: PMID 38003399\nParsed article 73: PMID 37940684\nParsed article 74: PMID 37770114\nParsed article 75: PMID 37734840\nParsed article 76: PMID 37147881\nParsed article 77: PMID 36416908\nParsed article 78: PMID 36261050\nParsed article 79: PMID 36249043\nParsed article 80: PMID 36140613\nParsed article 81: PMID 35902300\nParsed article 82: PMID 35556160\nParsed article 83: PMID 35045552\nParsed article 84: PMID 35032234\nParsed article 85: PMID 34954764\nParsed article 86: PMID 34933889\nParsed article 87: PMID 34902034\nParsed article 88: PMID 34772793\nParsed article 89: PMID 34729965\nParsed article 90: PMID 34633090\nParsed article 91: PMID 34439287\nParsed article 92: PMID 34395251\nParsed article 93: PMID 34373733\nParsed article 94: PMID 34284438\nParsed article 95: PMID 34049987\nParsed article 96: PMID 33958536\nParsed article 97: PMID 33866336\nParsed article 98: PMID 33783752\nParsed article 99: PMID 33754047\n"}
{"seq": 13, "ts": "2026-02-20T10:26:27.676881+00:00", "agent": "agent2", "cmd": "pm search PSMA PET metabolic tumor volume prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 15, "ts": "2026-02-20T10:27:07.387421+00:00", "agent": "agent2", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nCommands:\n  init        Initialize audit trail and cache (.pm/)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  quick       One-command search pipeline (outputs JSONL)\n\nExamples:\n  pm search \"CRISPR cancer\" | pm fetch | pm parse > results.jsonl\n  pm quick \"covid vaccine\" --max 50\n  pm filter --year 2024 --has-abstract < articles.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": ""}
{"seq": 16, "ts": "2026-02-20T10:27:14.553393+00:00", "agent": "agent2", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nExamples:\n  pm search \"CRISPR cancer therapy\"\n  pm search --max 100 \"machine learning\"\n  pm search \"covid vaccine 2024\" | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": ""}
{"seq": 18, "ts": "2026-02-20T10:29:28.379691+00:00", "agent": "agent2", "cmd": "pm fetch --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm fetch - Fetch PubMed XML from E-utilities API\n\nUsage: echo \"12345\" | pm fetch > articles.xml\n       cat pmids.txt | pm fetch > articles.xml\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nInput:\n  PMIDs from stdin, one per line\n\nOutput:\n  PubMed XML to stdout\n\nFeatures:\n  - Batches requests (200 PMIDs per API call)\n  - Rate limits to ~3 requests/second\n  - Exits with error on network failure\n\nExamples:\n  echo \"12345\" | pm fetch > article.xml\n  cat pmids.txt | pm fetch > articles.xml\n  pm search \"CRISPR\" | pm fetch | pm parse > results.jsonl\n", "stderr": ""}
{"seq": 19, "ts": "2026-02-20T10:29:34.809548+00:00", "agent": "agent2", "cmd": "pm parse --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm parse - Parse PubMed XML to JSONL\n\nUsage: cat articles.xml | pm parse [OPTIONS] > articles.jsonl\n       zcat articles.xml.gz | pm parse [OPTIONS] > articles.jsonl\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nOutput:\n  One JSON object per line (JSONL format) with fields:\n    pmid, title, authors, journal, year, date, doi, pmcid, abstract\n\nExamples:\n  cat pubmed.xml | pm parse > articles.jsonl\n  zcat pubmed25n0001.xml.gz | pm parse > articles.jsonl\n  cat pubmed.xml | pm parse --verbose > articles.jsonl 2>progress.log\n", "stderr": ""}
{"seq": 20, "ts": "2026-02-20T10:29:42.772284+00:00", "agent": "agent2", "cmd": "pm search metabolic tumor volume PSMA PET prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 21, "ts": "2026-02-20T10:29:49.621643+00:00", "agent": "agent2", "cmd": "pm search metabolic tumor volume PSMA PET prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 22, "ts": "2026-02-20T10:29:49.622525+00:00", "agent": "agent2", "cmd": "pm fetch -v 2", "exit_code": 0, "stdin_lines": 100, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\"><PMID Version=\"1\">41703276</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2730-664X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2026</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Communications medicine</Title><ISOAbbreviation>Commun Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Distinct prognostic value of [<sup>18</sup>F]FDG PET and [<sup>68</sup>Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s43856-026-01444-6</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">This study aimed to eva\n... [2144965 chars total, truncated] ...\nnd imaging derived parameters before and after two cycles of therapy. Nuklearmedizin. 2019;58:443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31724145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmuck S, von Klot CA, Henkenberens C. et al. Initial Experience with Volumetric 68Ga-PSMA I&amp;T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017;58:1962&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28522740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidkonz C, Cordes M, Schmidt D. et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29725716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>", "stderr": "Fetching batch 1 (100 PMIDs)...\n"}
{"seq": 24, "ts": "2026-02-20T10:30:14.767576+00:00", "agent": "agent2", "cmd": "pm search metabolic tumor volume PSMA PET prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41703276\n41635089\n41519653\n41490309\n41486328\n41454834\n41421031\n41363980\n41344853\n41287510\n41281171\n41266250\n41167722\n41067860\n41021003\n40967759\n40851054\n40788167\n40696478\n40665782\n40665456\n40647625\n40605658\n40551434\n40550326\n40517368\n40397137\n40278858\n40259392\n40247813\n40137974\n40137954\n40113645\n40001235\n39939019\n39893058\n39847077\n39821663\n39818681\n39794510\n39753363\n39745526\n39477497\n39473093\n39442347\n39313655\n39237346\n39219355\n39142831\n39110196\n39097169\n39094629\n39089299\n39082074\n39080696\n38980577\n38948055\n38835183\n38835182\n38832429\n38752520\n38726601\n38718704\n38693454\n38587770\n38563882\n38520513\n38298510\n38285206\n38199184\n38117551\n38003399\n37940684\n37770114\n37734840\n37147881\n33620825\n36416908\n36261050\n36249043\n36140613\n35902300\n35556160\n35045552\n35032234\n34954764\n34933889\n34902034\n34772793\n34729965\n34633090\n34439287\n34395251\n34373733\n34284438\n34049987\n33958536\n33866336\n33783752\n33754047\n", "stderr": ""}
{"seq": 23, "ts": "2026-02-20T10:30:14.764241+00:00", "agent": "agent2", "cmd": "pm fetch", "exit_code": 0, "stdin_lines": 100, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\"><PMID Version=\"1\">41703276</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2730-664X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2026</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Communications medicine</Title><ISOAbbreviation>Commun Med (Lond)</ISOAbbreviation></Journal><ArticleTitle>Distinct prognostic value of [<sup>18</sup>F]FDG PET and [<sup>68</sup>Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s43856-026-01444-6</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">This study aimed to eva\n... [2144965 chars total, truncated] ...\nnd imaging derived parameters before and after two cycles of therapy. Nuklearmedizin. 2019;58:443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31724145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmuck S, von Klot CA, Henkenberens C. et al. Initial Experience with Volumetric 68Ga-PSMA I&amp;T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017;58:1962&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28522740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidkonz C, Cordes M, Schmidt D. et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29725716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>", "stderr": ""}
{"seq": 25, "ts": "2026-02-20T10:30:29.801546+00:00", "agent": "agent2", "cmd": "pm parse 2", "exit_code": 0, "stdin_lines": 339, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were col\n... [412080 chars total, truncated] ...\nA. Patients with partial remission, independently assessed by each method, had better overall survival (OS) than patients with either stable or progressive disease. The difference in OS was statistically significant for the molecular imaging response assessment (median OS not reached vs. 8.3 m, p = 0.044), but not for the biochemical response assessment (median OS 18.1 m vs. 9.4 m, p = 0.468). Conclusion: Based on both assessment methods, [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy is an effective treatment for the highly challenging cohort of patients with mCRPC who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Molecular imaging response and biochemical PSA response were mostly concordant, though a considerable number of cases (29.4%) were discordant. Molecular imaging response reflecting the change in total viable tumour burden appears to be superior to PSA change in estimating survival outcome after tandem therapy.\", \"pmcid\": \"PMC7977444\", \"doi\": \"10.7150/thno.56211\"}\n", "stderr": ""}
{"seq": 26, "ts": "2026-02-20T10:30:48.012513+00:00", "agent": "agent2", "cmd": "pm parse", "exit_code": 0, "stdin_lines": 339, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were col\n... [412080 chars total, truncated] ...\nA. Patients with partial remission, independently assessed by each method, had better overall survival (OS) than patients with either stable or progressive disease. The difference in OS was statistically significant for the molecular imaging response assessment (median OS not reached vs. 8.3 m, p = 0.044), but not for the biochemical response assessment (median OS 18.1 m vs. 9.4 m, p = 0.468). Conclusion: Based on both assessment methods, [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy is an effective treatment for the highly challenging cohort of patients with mCRPC who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Molecular imaging response and biochemical PSA response were mostly concordant, though a considerable number of cases (29.4%) were discordant. Molecular imaging response reflecting the change in total viable tumour burden appears to be superior to PSA change in estimating survival outcome after tandem therapy.\", \"pmcid\": \"PMC7977444\", \"doi\": \"10.7150/thno.56211\"}\n", "stderr": ""}
{"seq": 27, "ts": "2026-02-20T10:31:01.681347+00:00", "agent": "agent2", "cmd": "pm filter --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm filter - Filter JSONL articles by field patterns\n\nUsage: pm parse | pm filter [OPTIONS]\n       cat articles.jsonl | pm filter [OPTIONS]\n\nFilter Options:\n  --year PATTERN      Year filter (exact, range, or open-ended)\n                      Examples: 2024, 2020-2024, 2020-, -2024\n  --journal PATTERN   Journal contains PATTERN (case-insensitive)\n  --journal-exact STR Journal equals STR exactly\n  --author PATTERN    Any author contains PATTERN (case-insensitive)\n  --has-abstract      Article has non-empty abstract\n  --has-doi           Article has DOI\n\nGeneral Options:\n  -v, --verbose       Show filter stats on stderr\n  -h, --help          Show this help\n\nExamples:\n  pm filter --year 2020- --journal nature --has-abstract\n  pm filter --author smith\n  pm filter --year 2020-2024\n\nNotes:\n  - Multiple filters combine with AND logic\n  - Malformed JSON lines are silently skipped\n", "stderr": ""}
{"seq": 28, "ts": "2026-02-20T10:31:29.335578+00:00", "agent": "agent2", "cmd": "pm filter --year 2023- --has-abstract", "exit_code": 0, "stdin_lines": 99, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were col\n... [320962 chars total, truncated] ...\n k4\u2009=\u20090.47 (2TCM, tumor, p\u2009=\u2009ns) indicated reversible binding. K1, an indicator for vascularization, increased (0.1/0.34, 21 to 28\u00a0days, p\u2009<\u20090.005). IFS confirmed co-expression of PSMA and tumor vascularization. [18F]fluciclovine showed higher TBR (2.5/1.8, p\u2009<\u20090.001, 60\u00a0min) and VS (1.3/0.7, p\u2009<\u20090.05, tumor) compared to [18F]FET and LA indicated reversible binding. VT increased (p\u2009<\u20090.001, tumor, 21 to 28\u00a0days) for [18F]FET (0.5-1.4) and [18F]fluciclovine (0.84-1.5).\"}, {\"label\": \"CONCLUSION\", \"text\": \"[18F]rhPSMA-7.3 showed to be a potential candidate to investigate the tumor microenvironment of GBM. Following PKM, this uptake was associated with tumor vascularization. In contrast to what is known from PSMA-PET in prostate cancer, reversible binding was found for [18F]rhPSMA-7.3 in GBM, contradicting cellular trapping. Finally, [18F]fluciclovine was superior to [18F]FET rendering it more suitable for PET imaging of GBM.\"}], \"pmcid\": \"PMC9931868\", \"doi\": \"10.1007/s00259-022-06040-z\"}\n", "stderr": ""}
{"seq": 29, "ts": "2026-02-20T10:31:45.231171+00:00", "agent": "agent2", "cmd": "pm cite --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm cite - Fetch CSL-JSON citations from NCBI Citation Exporter API\n\nUsage: echo \"12345\" | pm cite > citations.jsonl\n       pm cite 12345 67890 > citations.jsonl\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nOutput:\n  JSONL format (one CSL-JSON object per line)\n", "stderr": ""}
